tm logo
MIRACLE MOLECULE
Dead/Abandoned
ABANDONED - FAILURE TO RESPOND OR LATE RESPONSE

failure to respond or late response

on 17 Jun 2023

Last Applicant/ Owned by

P.O. BOX 421997

HOUSTON

TX

77242

Serial Number

88481887 filed on 20th Jun 2019

Registration Number

N/A

Correspondent Address

Ava K. Doppelt, Esq.

Ava K. Doppelt, Esq.

255 South Orange Avenue, Suite 1401

Orlando FL 32801

Filing Basis

1. intent to use

2. intent to use current

Disclaimer

NO DATA

MIRACLE MOLECULE

Patented kit for concentrating Alpha 2 Macroglobulin in human blood, comprised of medical syringes, medical tubing for blood collection, and filters for blood and blood components for medical purposes

Classification Information


Class [010]
Medical Instrument Products


Patented kit for concentrating Alpha 2 Macroglobulin in human blood, comprised of medical syringes, medical tubing for blood collection, and filters for blood and blood components for medical purposes


First Use Date in General

01st May 2018

First Use Date in Commerce

01st May 2018

Specimens


MIRACLE MOLECULE specimenMIRACLE MOLECULE specimenMIRACLE MOLECULE specimenMIRACLE MOLECULE specimenMIRACLE MOLECULE specimenMIRACLE MOLECULE specimenMIRACLE MOLECULE specimenMIRACLE MOLECULE specimenMIRACLE MOLECULE specimen

Mark Details


Serial Number

No 88481887

Mark Type

No Service/Collective Mark

Attorney Docket Number

No 132953

44D Filed

No

44D Current

No

44E filed

No

44E Current

No

66A Filed

No

66A Current

No

Current Basis

No

No Basis

No

Legal History


Show more

Status DateAction Taken
20th Jun 2023ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
17th Jun 2023ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
17th Jun 2023ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND
01st Feb 2023NON-FINAL ACTION E-MAILED
01st Feb 2023SU - NON-FINAL ACTION - WRITTEN
01st Feb 2023NOTIFICATION OF NON-FINAL ACTION E-MAILED
19th Dec 2022CORRESPONDENCE RECEIVED IN LAW OFFICE
19th Dec 2022ASSIGNED TO LIE
19th Dec 2022TEAS/EMAIL CORRESPONDENCE ENTERED
12th Dec 2022TEAS RESPONSE TO OFFICE ACTION RECEIVED